| Literature DB >> 26878343 |
Nicholas F Pelz1, Zhiguo Bian1, Bin Zhao1, Subrata Shaw1, James C Tarr1, Johannes Belmar1, Claire Gregg1, DeMarco V Camper1, Craig M Goodwin1, Allison L Arnold1, John L Sensintaffar1, Anders Friberg1, Olivia W Rossanese1, Taekyu Lee1, Edward T Olejniczak1, Stephen W Fesik1.
Abstract
Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family of proteins responsible for the regulation of programmed cell death. Amplification of Mcl-1 is a common genetic aberration in human cancer whose overexpression contributes to the evasion of apoptosis and is one of the major resistance mechanisms for many chemotherapies. Mcl-1 mediates its effects primarily through interactions with pro-apoptotic BH3 containing proteins that achieve high affinity for the target by utilizing four hydrophobic pockets in its binding groove. Here we describe the discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design. These novel inhibitors exhibit low nanomolar binding affinities to Mcl-1 and >500-fold selectivity over Bcl-xL. X-ray structures of lead Mcl-1 inhibitors when complexed to Mcl-1 provided detailed information on how these small-molecules bind to the target and were used extensively to guide compound optimization.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26878343 PMCID: PMC5565212 DOI: 10.1021/acs.jmedchem.5b01660
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446